Railway Pension Investments Ltd Trims Holdings in IDEXX Laboratories, Inc. $IDXX

Railway Pension Investments Ltd reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 82.3% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 45,360 shares of the company’s stock after selling 211,120 shares during the quarter. Railway Pension Investments Ltd’s holdings in IDEXX Laboratories were worth $23,879,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in IDXX. Elyxium Wealth LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $3,666,459,000. State Street Corp raised its position in IDEXX Laboratories by 4.0% in the 4th quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after purchasing an additional 138,956 shares during the last quarter. J. Stern & Co. LLP increased its holdings in shares of IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after purchasing an additional 2,642,200 shares during the period. Geode Capital Management LLC boosted its holdings in shares of IDEXX Laboratories by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after acquiring an additional 86,263 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in IDEXX Laboratories by 13.8% in the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock valued at $1,016,296,000 after purchasing an additional 181,955 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IDXX. Barclays cut their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Citigroup lifted their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Finally, UBS Group lifted their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $747.00.

IDEXX Laboratories Trading Up 0.3%

IDEXX Laboratories stock opened at $556.69 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The firm’s 50-day moving average is $559.23 and its 200-day moving average is $572.70. IDEXX Laboratories, Inc. has a 1 year low of $518.55 and a 1 year high of $769.98. The company has a market cap of $43.86 billion, a P/E ratio of 39.15, a PEG ratio of 2.96 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period last year, the business posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.